Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer

Research output: Contribution to journalArticlepeer-review


Background: Multidisciplinary management of oligometastatic breast cancer with local therapy could improve disease control. The aim of our study is the assessment of safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) in selected subset of patients. Patients and methods: Oligometastastic patients from breast cancer were treated with SBRT for 1-3 lung and liver lesions, in an observational study. Inclusion criteria were: age >18 years, ECOG 0-2, diagnosis of breast cancer, no extrapulmonary and/or extrahepatic disease, other metastatic sites stable or responding after chemotherapy were allowed, no life threatening conditions, less than 5 lung and liver lesions (with maximum diameter 12 months, hormonal receptor positivity, medical therapies after SBRT showed a significant impact on OS. Treatment was well tolerated, with no G3-4 toxicities. Conclusions: SBRT is a safe and feasible alternative treatment of liver and lung oligometastases from breast cancer, in selected patients not amenable to surgery, with good local control and survival rate.

Original languageEnglish
Pages (from-to)11-17
Number of pages7
Publication statusPublished - Apr 1 2016


  • Breast cancer
  • Liver
  • Lung
  • RapidArc
  • Stereotactic body radiation therapy

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer'. Together they form a unique fingerprint.

Cite this